| Clinical Feature |
Score |
| Female gender |
+2 |
| ALP:AST ratio |
|
| <1.5 |
+2 |
| 1.5-3.0 |
0 |
| >3.0 |
-2 |
| Serum globulin or IgG above normal |
|
| >2.0 |
+3 |
| 1.5-2.0 |
+2 |
| 1.0-1.5 |
+1 |
| <1.0 |
0 |
| ANA, SMA, or LKM-1 |
|
| >1:80 |
+3 |
| 1:80 |
+2 |
| 1:40 |
+1 |
| <1:40 |
0 |
| AMA |
|
| positive |
-4 |
| Hepatitis viral markers |
|
| Positive |
-3 |
| Negative |
+3 |
| Drug history |
|
| Positive |
-4 |
| Negative |
+1 |
| Average alcohol intake |
|
| <25 g/day |
+2 |
| >60 g/day |
-2 |
| Liver histology |
|
| Interface hepatitis |
+3 |
| Predominante lymphoplasmacytic infiltrate |
+1 |
| Rosetting of liver cells |
+1 |
| None of the above |
-5 |
| Biliary changes |
-3 |
| Other changes |
-3 |
| Other autoimmune disease |
+2 |
| Optional additional parameters |
|
| Seropositivity for other defined autoantibodies |
+2 |
| HLA DR3 or DR4 |
+3 |
| Response to therapy |
|
| Complete |
+2 |
| Relapse |
+3 |
| Interpretation of aggregate scores: |
|
| Pre-treatment |
|
| Definite AIH |
>15 |
| Probable AIH |
10-15 |
| Post-treatment |
|
| Definite AIH |
>17 |
| Probable AIH |
12-17 |
ALP: Alkaline Phosphatase; AST: Aspartate Transaminase; IgG: Immunoglobulin
G; ANA: Anti-nuclear Antibodies; SMA: Smooth Muscle Antibodies; LKM-1: Type
1 Liver-kidney Microsomal antibodies; AMA: Anti-Mitochondrial Antibodies; HLA:
Human Leucocyte Antigen |
